Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | HTR2C | P28335 | 6/20 | 0.33 |
| ▸ | HTR2B | P41595 | 6/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314875 | 1.00 | HTR2A (0.33) | HTR2AHTR2CHTR2BACHEKCNH2 | |
| SCHEMBL28525363 | 1.00 | HTR2A (0.33) | HTR2AHTR2CHTR2BACHEKCNH2 | |
| SCHEMBL868218 | 0.89 | ACHE (0.41) | HTR2AHTR2CHTR2BACHEKCNH2 | |
| SCHEMBL14884980 | 0.89 | ACHE (0.41) | HTR2AHTR2CHTR2BACHEKCNH2 | |
| SCHEMBL10287316 | 0.89 | ACHE (0.41) | HTR2AHTR2CHTR2BACHEKCNH2 | |
| SCHEMBL29814887 | 0.89 | ACHE (0.41) | HTR2AHTR2CHTR2BACHEKCNH2 | |
| SCHEMBL30496837 | 0.84 | ACHE (0.31) | ACHEHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL24490883 | 0.77 | ACHE (0.30) | ACHE | |
| SCHEMBL17768603 | 0.77 | HTR3E (0.38) | HTR2AHTR2CHTR2BKCNH2HTR3E | |
| SCHEMBL21332750 | 0.77 | ACHE (0.30) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2023-07-27 | — | — | US | disclosed |
| EP-4153591-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | Recurium IP Holdings, LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021252667-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252667-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-01 | — | — | US | disclosed |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-2432555-B1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2432555-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110130384-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2298731-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER. INC | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094948-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HTR2A 3475/4885HTR2C 3262/4885HTR2B 3398/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | HTR2A 3593/4885HTR2C 2146/4885HTR2B 3080/4885 |
| US-20110130384-A1 | AMIDE COMPOUND | GPR52, CNR2, ARRB1 | HTR2A 179/4885HTR2C 207/4885HTR2B 164/4885 |
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | HTR2C, HTR2A, HTR5A | HTR2A 2/4885HTR2C 1/4885HTR2B 4/4885 |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | HTR2A 3414/4885HTR2C 3193/4885HTR2B 3279/4885 |
| US-20230234956-A1 | METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS | WEE1, WEE2, CCNE1 | HTR2A 4557/4885HTR2C 4285/4885HTR2B 4632/4885 |
| US-10647713-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | HTR2A 3475/4885HTR2C 3262/4885HTR2B 3398/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | HTR2A 4525/4885HTR2C 4701/4885HTR2B 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.